JOINN's Analysis and Clinical Team Went to Wuhan to help with Novel Coronavirus New Drug R&D
2020-02-16
As of February 16, 68,594 cases of COVID-19 have been confirmed nationwide, and 39,462 cases have been confirmed in Wuhan. The development of the epidemic affects the hearts of the people all over the country, and also deeply strikes the hearts of JOINN people. There is no specific drug for novel coronavirus and its severe pneumonia, and there is an urgent need to accelerate the research and development of safe and effective new drugs and vaccines. To this end, domestic pharmaceutical companies and research institutions are working overtime to develop anti-coronavirus drugs. Drug authorities have also been working on approval at a rapid pace, and several new drugs have been approved for clinical trials. In order to accelerate the development of new drugs, for which to be used in patients as soon as possible to control the epidemic, JOINN has decided to establish a biological analysis capability in Wuhan to carry out serum sample testing and support safety and efficacy evaluation.
After hearing the news of going to Wuhan, every staff in JOINN wants to serve the country and the people, to make their lives more valuable. After comprehensive consideration, the company selected three analysts (Hongzhen Li, Lei Li and Xi Wang) and two clinical operation personnel (Mingming Wang and Tianxu Zhao) to form the first batch of JOINN Commandos. After passing the professional protection training and examination, they started the journey in Wuhan.
The Commandos, carrying the first batch of supplies, arrived in Wuhan at 4 p.m. on the 15th. The second batch of equipment and supplies also arrived in Wuhan on February 16. Clinical team has entered the hospital to start their work, and analytical team has also started the installation and commissioning of analytical equipment and other preparatory work for the trial, which will be carried out in the near future.
The journey also received strong support from leaders at all levels and multiple departments of Beijing and the Economic and Technological Development Zone. The customs opened up a green customs clearance channel, so that protective materials and test supplies could be cleared, purchased and delivered to the station in time.
JOINN will continue sending more personnel to Wuhan and other parts of the country according to the need. JOINN people have been ready to concentrate resources to provide platform services to support the research and development of the new drugs. To promote the early launch of new drugs, eliminate the new coronavirus and eliminate COVID-19.
Life is of paramount importance. When an epidemic breaks out, a command is issued. It is our responsibility to prevent and control it.
【JOINN Open up the Green Channel】
As the most complete non-clinical platform for drug assessment in China, JOINN has rich experience in the safety assessment of antiviral drugs, antiviral drugs and vaccines such as SARS, H5N1, H7N9 and Ebola virus. In view of the SARS-CoV-2 epidemic, the company has set up a strong expert team and established a green service channel, to ensure that JOINN could give full participation in the guidance, rapid evaluation, cooperate with the technical communication of CDE for all kinds of anti-SARS-CoV-2 drugs.